Fragment 176-191 5mg

Description

Fragment 176-191: A History and Overview

Fragment 176-191, a synthetic peptide derived from human growth hormone (HGH), has been the focus of research for its potential in promoting fat loss and cartilage regeneration without the traditional side effects associated with HGH, such as increased blood sugar levels or altered insulin sensitivity. This peptide targets the reduction of fat reserves, specifically by enhancing lipolytic activity—the breakdown of fat—while inhibiting lipogenesis, the conversion of non-food material into fat​​​​.

Mechanism of Action

The peptide operates by mimicking the way natural growth hormone regulates fat metabolism but without affecting blood sugar levels or insulin sensitivity, making it a targeted approach to fat loss. It stimulates lipolysis and blocks lipogenesis, offering a promising solution for weight management without the risk of developing cardiometabolic disorders like Type 2 Diabetes Mellitus​​​​.

Chemical Composition

• Chemical Structure: The peptide sequence for Fragment 176-191 is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, which represents a small portion of the larger HGH molecule that is thought to be responsible for its fat-burning properties.
• CAS: 66004-57-7 (free base)
• Chemical Name: HGH Frag 176-191; Human growth hormone (176-191); HGH (176-191); FLRIVQCRSVEGSCGF; Phe-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe AcOH
• Molecular Formula: The molecular formula is specific to its amino acid sequence, reflecting the composition and arrangement of carbon, hydrogen, nitrogen, oxygen, and sulfur atoms in the peptide.
• Stability: This peptide exhibits a good degree of stability, retaining its structure and activity when stored properly (typically in lyophilized form at low temperatures).
• Solubility: Fragment 176-191 is soluble in water and most aqueous buffers, making it suitable for subcutaneous injection, which is the most common route of administration.
• Mechanism of Action: The exact mechanism of action is not fully understood, but it is believed to mimic the way natural growth hormone regulates fat metabolism but without the adverse effects on insulin sensitivity (blood sugar levels) or cell proliferation that is seen with unmodified HGH.
• Fat Loss Properties: Research suggests that Fragment 176-191 selectively stimulates lipolysis (the breakdown of fat) in adipocytes (fat cells) and inhibits lipogenesis (the formation of fatty acids and triglycerides in the body), which makes it a promising candidate for the promotion of fat loss.
• No Significant Impact on Growth or Insulin Resistance: Unlike full-length HGH, which can promote bone and muscle growth as well as impact blood sugar levels, Fragment 176-191 is believed to not significantly affect blood sugar levels or contribute to the growth of bones and muscles due to its specific action on fat cells.
• Safety Profile: As with many peptides, comprehensive safety and long-term health effects are not fully established. Studies, primarily in animals, suggest a good safety profile, but human data are limited.
• Legal Status and Availability: Fragment 176-191 is often marketed as a research chemical and is not approved by the FDA or other regulatory bodies for medical use. It is available through various online sources for research purposes.
• Shelf Life: 36 months
• Appearance: White lipolyzed powder puck.

Clinical Trials and Research

Although Fragment 176-191 has shown promise in preclinical studies, particularly in reducing body weight in obese mice and potentially offering benefits in muscle recovery and anti-aging, human studies are limited. The peptide’s exact mechanism of action remains not fully understood, and more research is needed to confirm these findings and fully grasp its safety profile​​​​.

Benefits and Uses

Fragment 176-191 is lauded for its fat-burning capabilities without the severe side effects associated with full-length HGH. It has been noted to regulate blood glucose levels beneficially, mitigate the risk of developing cardiometabolic diseases, and potentially support musculoskeletal health. In bodybuilding, it’s used during the cutting phase to decrease fat reserves while attempting to preserve muscle mass​​.

Dosage Guidelines

The dosage of Fragment 176-191 can vary depending on individual goals and needs, with common recommendations ranging from 200 mcg up to 300 mcg per day, divided into multiple doses. It’s crucial to consult with a healthcare provider to determine the appropriate dosage and administration method, ensuring it aligns with one’s health status and fitness goals​​​​.

Considerations

Despite its potential, Fragment 176-191’s use comes with considerations. Its legality varies, and it is not FDA approved for over-the-counter use, being available primarily for research purposes. Users should be aware of the peptide’s research status and obtain it from reputable sources to ensure quality and purity​​.

In summary, Fragment 176-191 represents a promising area of research within the realm of peptides aimed at fat loss and metabolic health. While initial findings highlight its potential, comprehensive human studies are necessary to fully understand its effects, optimal dosage, and long-term safety. As with any peptide or supplement, professional medical advice is recommended before incorporating it into a health or fitness regimen.

Referenced Citations

1. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells (https://pubmed.ncbi.nlm.nih.gov/35783198/)
2. Detection and in vitro metabolism of AOD9604
   (https://pubmed.ncbi.nlm.nih.gov/25212235/)
3. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone
   (https://pubmed.ncbi.nlm.nih.gov/9077582/)
4. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
   (https://pubmed.ncbi.nlm.nih.gov/12788493/)
5. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism (https://pubmed.ncbi.nlm.nih.gov/10970796/)
6. Antilipogenic action of synthetic C-terminal sequence 177-191 of the human growth hormone
   (https://pubmed.ncbi.nlm.nih.gov/11344207/)
7. Pancreatic effect of a hypoglycaemic fragment of human growth hormone
   (https://pubmed.ncbi.nlm.nih.gov/23755547/)
8. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) predicts cardiovascular events or death (https://pubmed.ncbi.nlm.nih.gov/15507526/)
9. Systematic Review of Hospital Readmissions Among Patients With Cancer
   (https://pubmed.ncbi.nlm.nih.gov/28113019/)
10. A fragment-based approach to identifying S-adenosyl-l-methionine (SAM) binding pocket inhibitors of catechol O-methyltransferase (COMT) (https://pubmed.ncbi.nlm.nih.gov/28627883/)